| HSV-2 shedding | HIV shedding | |||
| Acyclovir | Placebo | Acyclovir | Placebo | |
| Number randomly assigned | N = 69 (%) | n = 56 (%) | ||
| Visit number | ||||
| 1 | 4/58 (7) | 12/51 (24)* | 44/58 (76) | 35/51 (69) |
| 2 | 3/62 (5) | 13/47 (28)* | 40/62 (65) | 29/47 (62) |
| 3 | 1/54 (2) | 12/49 (24)* | 26/54 (48) | 27/49 (55) |
| 4 | 6/55 (11) | 9/43 (21) | 36/54 (67) | 22/43 (51) |
| 5 | 9/58 (16) | 11/47 (23) | 39/58 (67) | 27/47 (58) |
| 6 | 7/52 (13) | 7/39 (18) | 35/52 (67) | 23/39 (59) |
| 7 | 6/54 (11) | 9/44 (20) | 30/54 (56) | 29/44 (66) |
| 8 | 6/52 (12) | 6/39 (15) | 18/52 (73) | 27/39 (69) |
| 9 | 3/49 (6) | 10/41 (24)* | 33/49 (67) | 25/40 (63) |
| 10 | 6/53 (11) | 13/45 (29)* | 39/53 (74) | 31/45 (69) |
| 11 | 7/49 (14) | 10/44 (23) | 33/49 (67) | 28/44 (64) |
| 12 | 6/50 (12) | 11/42 (26) | 37/50 (74) | 29/42 (69) |
| Overall shedding | 64/646 (10%) | 123/531 (23%) | 430/645 (67%) | 332/530 (63%) |
| Univariate odds ratio | 0.24 (95% CI 0.12 to 0.50; <p<0.001) | 1.18 (95% CI 0.48 to 2.9; p = 0.7) | ||
| Adjusted odds ratio† | 0.24 (95% CI 0.12 to 0.48; <p<0.001) | 1.08 (95% CI 0.48 to 2.42; p = 0.9) | ||
*The difference in rates of herpes simplex virus type 2 (HSV-2) shedding is significantly lower among acyclovir recipients at this visit (p<0.05). No statistically significant difference in rates of HIV shedding were seen at any visit.
†Adjusted for CD4 cell count and plasma viral load at baseline.